39 citations
,
January 2019 in “Journal of the American Academy of Dermatology” Tofacitinib may help treat severe childhood alopecia areata, but risks require careful consideration.
5 citations
,
August 2024 in “Frontiers in Immunology” Upadacitinib effectively treats psoriasiform eczema and some related conditions.
December 2024 in “Drug Discoveries & Therapeutics” Baricitinib-loaded EVs help hair regrowth in alopecia areata by reducing inflammation and promoting hair follicle regeneration.
January 2022 in “Drugs of Today”
3 citations
,
March 2023 in “JAAD case reports” Upadacitinib cleared scalp alopecia areata in three patients and also improved atopic dermatitis with minimal side effects.
1 citations
,
May 2019 in “Journal of pediatric endocrinology & metabolism/Journal of pediatric endocrinology and metabolism” Intravenous calcium therapy is a safe and effective treatment for a rare type of rickets.
January 2024 in “Pharmaceutical journal/The pharmaceutical journal” Ritlecitinib can help about 14,000 people with severe hair loss.
Ritlecitinib improves hair regrowth in alopecia areata without increasing adverse risks.
2 citations
,
April 2019 in “Dermatologic Therapy” A patient with alopecia had hair regrowth with tofacitinib but developed a skin reaction, choosing to continue the treatment despite the side effect.
2 citations
,
January 2025 in “Journal of Clinical Immunology”
Dacomitinib can cause nail and skin issues, but these can be managed without stopping the drug.
1 citations
,
May 2017 in “Journal of the American Academy of Dermatology” Tofacitinib helped a teenager with severe hair loss grow hair back, but more research is needed.
January 2025 in “The Journal of Dermatology” Patients prefer the higher 50 mg dose of ritlecitinib for better hair regrowth despite higher risks.
April 2025 in “European Journal of Pharmaceutics and Biopharmaceutics” The new drug delivery system improves bicalutamide skin retention for better treatment of hair loss.
16 citations
,
January 2017 in “Acta dermatovenerologica Alpina, Pannonica et Adriatica (Tiskana izd.)” A patient with complete hair loss regrew all her hair using tofacitinib.
January 2025 in “Journal of Crohn s and Colitis” Tofacitinib is effective and safe for elderly patients with ulcerative colitis.
24 citations
,
January 2018 in “International Journal of Trichology” Tofacitinib helped regrow hair in patients with alopecia, with few side effects.
January 2023 in “Cutaneous and Ocular Toxicology” December 2025 in “Dermatology Reports” Topical ruxolitinib quickly improves non-segmental vitiligo.
May 2025 in “Immunotherapy” Patients were very satisfied with hair regrowth after taking ritlecitinib for alopecia areata.
September 2024 in “Skin Appendage Disorders” Tofacitinib helped a woman regrow her hair without relapses after other treatments failed.
March 2022 in “Oncology Times” Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.
2 citations
,
May 2025 in “Journal of Clinical Medicine” Upadacitinib is safe and effective for treating alopecia areata and atopic dermatitis in children.
66 citations
,
December 2018 in “Dermatology” Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib effectively promotes hair regrowth in severe and very severe alopecia areata.
March 2023 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib helped most alopecia areata patients regrow hair by Week 48.
January 2018 in “Figshare” Ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata.
Switching JAK inhibitors can lead to significant hair regrowth in severe alopecia cases.
7 citations
,
November 2023 in “JAAD Case Reports” Baricitinib helped regrow hair in patients with severe alopecia areata after other treatments failed.
41 citations
,
December 2015 in “JAMA Dermatology” Tofacitinib citrate improved nail dystrophy and pain in patients with alopecia universalis without causing side effects.